RevitalVision announced the publication of positive clinical data for its digital therapeutic treatment for infantile nystagmus in the British Journal of Ophthalmology. According to a company press release, the study provides the first randomized controlled evidence that RevitalVision, an FDA-cleared neuroplasticity-based visual training program, can improve visual function in patients with infantile nystagmus, a congenital eye movement disorder present from early infancy, characterized by involuntary, rhythmic oscillations of the eyes. 

The study, titled “Efficacy of perceptual learning among patients with infantile nystagmus,” conducted at Shamir Medical Center in Israel, evaluated a structured program of visual perceptual exercises designed to enhance cortical visual processing. Patients participating in the trial demonstrated statistically significant improvements in visual acuity, contrast sensitivity, and functional vision, confirming that targeted perceptual learning can enhance visual performance in this population, according to the press release.

Specifically, the study showed that significant improvement was measured in near and distance best-corrected visual acuity enabling 46% of treated subjects to achieve driving-license vision of 20/40. In addition, significant improvements were measured in contrast sensitivity, stereoacuity, and binocular vision. Finally, 50% (13/26) of the study patients reported subjective improvements in both distance and near vision, while 42% (11/26) noted enhanced night vision and 76.9% (20/26) would recommend the treatment to others.

"Patient-reported outcomes indicate that the visual improvements observed in the study had a tangible impact on daily functioning, not just on clinical test results" said Dr. Sigal Zmujack-Yehiam, the lead researcher of the study.

Yair Yahav, founder and CEO, RevitalVision, added that "this study provides new hope to millions of people living with infantile nystagmus."